In vivo detection of Alzheimer's and Lewy body disease concurrence

Baiardi, Simone; Hansson, Oskar; Levin, Johannes und Parchi, Piero (2024): In vivo detection of Alzheimer's and Lewy body disease concurrence. Clinical implications and future perspectives. In: Alzheimer's & Dementia, Bd. 20, Nr. 8: S. 5757-5770

Abstract

Introduction: The recent introduction of seed amplification assays (SAAs) detect-ing misfolded α-synuclein, a pathology-specific marker for Lewy body disease (LBD), has allowed the in vivo identification and phenotypic characterization of patients with co-occurring Alzheimer’s disease (AD) and LBD since the early clinical or even preclinical stage. Methods: We reviewed studies with an in vivo biomarker-based diagnosis of AD-LBD copathology. Results: Studies in large cohorts of cognitively impaired individuals have shown that cerebrospinal fluid (CSF) biomarkers detect the coexistence of AD and LB pathology in approximately 20%–25% of them, independently of the primary clinical diagnosis. Compared to those with pure AD, AD-LBD patients showed worse global cognition, especially in attentive/executive and visuospatial functions, and worse motor func-tions. In cognitively unimpaired individuals, concurrent AD-LBD pathologies predicted longitudinal cognitive progression with faster worsening of global cognition, memory, and attentive/executive functions.Discussion: Future research studies aiming for a better precision medicine approach should develop SAAs further to reach a quantitative evaluation or staging of each underlying pathology using a single biofluid sample.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin > Munich Cluster for Systems Neurology (SyNergy) ; Medizin > Klinikum der LMU München > Neurologische Klinik und Poliklinik mit Friedrich-Baur-Institut
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1552-5260
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198